C$0.2 -0.0 -16.7%
Last Trade - 26/02/21
| Market Cap | £451k |
| Enterprise Value | £311k |
| Revenue | £n/a |
| Position in Universe | th / 2684 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Sep | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010E | 2011E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Biocure Technology Inc, formerly Gravis Energy Corp, is a Canada based company that is engaged in the Bio Pharmaceutical sector. The Company operates through BiocurePharm, a South Korean-based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. BiocurePharm is in the process of clinical trials of five biosimilar products in South Korea, including Interferon Beta 1b, Filgrastim and Ranibizumab. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (MS); Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions; Ranibizumab is used for treating macular degeneration. BiocurePharm is also developing a foot and mouth disease vaccine, a hair growth production product and a breast cancer detection kit.
| Last Annual | September 30th, 2009 |
| Last Interim | December 31st, 2009 |
| Incorporated | August 24, 2007 |
| Public Since | March 27, 2008 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Address | 300 - 1055 West Hastings Street, VANCOUVER, V6E 2E9, Canada |
| Web | https://biocuretech.com/ |
| Phone | +1 604 6097149 |
| Contact | () |
| Auditors | BDO Canada LLP |
As of 26/02/21, shares in Biocure Technology Inc are trading at C$0.2, giving the company a market capitalisation of £451k. This share price information is delayed by 15 minutes.
Shares in Biocure Technology Inc are currently trading at C$0.2 and the price has moved by -37.5% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biocure Technology Inc price has moved by -44.22% over the past year.
There are no analysts currently covering Biocure Technology Inc.
Biocure Technology Inc is scheduled to issue upcoming financial results on the following dates:
Biocure Technology Inc does not currently pay a dividend.
Biocure Technology Inc does not currently pay a dividend.
Biocure Technology Inc does not currently pay a dividend.
To buy shares in Biocure Technology Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biocure Technology Inc are currently trading at C$0.2, giving the company a market capitalisation of £451k.
Here are the trading details for Biocure Technology Inc:
We were not able to load our ranking data for Biocure Technology Inc
We were not able to load any forecast data for Biocure Technology Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocure Technology Inc. Over the past six months, the relative strength of its shares against the market has been 0.69%. At the current price of C$0.2, shares in Biocure Technology Inc are trading at -13.4% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Biocure Technology Inc.
We were unable to find the directors for Biocure Technology Inc.
Here are the top five shareholders of Biocure Technology Inc based on the size of their shareholding:
